Stock Events

Stock Events

Search...

CUREVAC

€3.37

294

-€0.03-0.76% Monday 07:00

Statistics

Day High

3.37

Day Low

3.37

52W High

5.44

52W Low

2.16

Volume

257

Avg. Volume

2,871

Mkt Cap

-

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

22MayConfirmed

Q1 2024

-0.23

0.11

0.44

0.77

Expected EPS

-0.22822105865363998

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 1CVAC.MI. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

BioNTech SE is a direct competitor in the mRNA technology space, focusing on developing vaccines and therapeutics, similar to CureVac's core business.

Moderna, Inc. is a leader in mRNA therapeutics and vaccines, directly competing with CureVac in the COVID-19 vaccine market and other therapeutic areas.

Pfizer Inc., in collaboration with BioNTech, competes in the mRNA vaccine market, particularly with their COVID-19 vaccine, which is in direct competition with CureVac's development.

Novavax, Inc. competes in the vaccine space, particularly with its protein-based COVID-19 vaccine, offering an alternative to mRNA vaccines like those developed by CureVac.

Johnson & Johnson

Johnson & Johnson competes in the vaccine market with its viral vector COVID-19 vaccine, offering an alternative approach to CureVac's mRNA technology.

AstraZeneca PLC competes with its viral vector COVID-19 vaccine, which is a different technology but serves the same market as CureVac's vaccine candidates.

Sanofi competes in the vaccine and therapeutic market, working on mRNA vaccines and other technologies that could compete with CureVac's products.

GlaxoSmithKline plc competes in the vaccine space, including collaborations on COVID-19 vaccines and other therapeutic areas that overlap with CureVac's interests.

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc. is involved in the development of mRNA vaccines and therapeutics, making it a direct competitor in the same technology space as CureVac.

Translate Bio, now a part of Sanofi, focuses on mRNA technologies for vaccines and therapeutics, directly competing with CureVac in the mRNA space.

About

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.

Show more...

CEO

Mr. Pierre Kemula B.Sc.

Employees

999

Country

NL

ISIN

NL0015436031

WKN

000A2P71U

Listings